Novartis Group: The selection of sacubitril/valsartan tablets in this centralized procurement involves the indication of heart failure for this product.

According to news from Novartis Group, the results of the twelfth batch of national centralized procurement of drugs were announced on July 31, and Novartis' sacubitril/valsartan sodium tablets were selected in this centralized procurement. This procurement selection involves the indication for heart failure of the product. Additionally, according to public information from the National Intellectual Property Administration, one of the core patents owned by Novartis for sacubitril/valsartan sodium tablets has received a 1,826-day patent term extension based on its market approval for primary hypertension indication, with the extended patent protection period expiring on November 8, 2031.